China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1, US11530195B1) in relation to a development project titled “Coronavirus 3CL Protease Inhibitor Development,” in collaboration with Shaanxi University of Science and Technology. The patents cover “PROTACs [proteolysis-targeting chimeric molecules] based on VHL ligand targeting coronavirus 3CL protease, preparation method and application thereof.”
Patent Details and Innovation
The two patents are based on PROTACs designed and synthesized based on PLC01, the company’s novel coronavirus 3CL protease inhibitor drug candidate. Cell and animal experiments have shown that the PROTACs developed have excellent 3CL protease degradation ability. This marks the first time that anti-coronavirus PROTACs have received patent protection worldwide, highlighting Shaanxi Panlong’s leadership in innovative drug development.
Future Prospects and Strategic Implications
The receipt of these patents positions Shaanxi Panlong to further advance its research and development efforts in the field of coronavirus treatments. By leveraging the innovative PROTAC technology, the company aims to address significant unmet medical needs and contribute to the global fight against coronavirus infections. This strategic move underscores Shaanxi Panlong’s commitment to innovation and improving patient outcomes through advanced therapeutic solutions.-Fineline Info & Tech
